GSK has news on that front today, as well, reporting that the phase 2/3 COSTAR trial of Jemperli with experimental TIM-3 antagonist cobolimab will move into the phase 3 stage on the advice of its ...
1 MAbSilico SAS, Tours, France 2 Etablissement Français du Sang - Bourgogne Franche-Comté (EFS BFC), Plateforme ITAC-UMR1098-RIGHT, Besançon, France Antibody discovery is a lengthy and labor-intensive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback